|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: BESIVANCE
Summary for Tradename: BESIVANCE
|
| |||||||||
Clinical Trials for: BESIVANCESafety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children Status: Recruiting Condition: Congenital Nasolacrimal Duct Obstruction Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Status: Completed Condition: Bacterial Conjunctivitis Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis Status: Recruiting Condition: Bacterial Conjunctivitis Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation Status: Completed Condition: Healthy 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Status: Completed Condition: Corneal Health; Cataract Surgery Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects Status: Completed Condition: Cataract Extraction Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis Status: Terminated Condition: Bacterial Conjunctivitis Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Status: Recruiting Condition: Cataracts Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Status: Completed Condition: Bacterial Conjunctivitis A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery Status: Recruiting Condition: Cataracts Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb | BESIVANCE | besifloxacin hydrochloride | SUSPENSION/DROPS; OPHTHALMIC | 022308 | May 28, 2009 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bausch And Lomb | BESIVANCE | besifloxacin hydrochloride | SUSPENSION/DROPS; OPHTHALMIC | 022308 | May 28, 2009 | RX | Yes | 5,447,926 | Y | Y | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bausch And Lomb | BESIVANCE | besifloxacin hydrochloride | SUSPENSION/DROPS; OPHTHALMIC | 022308 | May 28, 2009 | RX | Yes | 6,685,958 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bausch And Lomb | BESIVANCE | besifloxacin hydrochloride | SUSPENSION/DROPS; OPHTHALMIC | 022308 | May 28, 2009 | RX | Yes | 6,699,492 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc